Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma

Cancer Science

Volumn 99, Issue 10, 2008, Pages 2097-2103

  Iida, Tomonori ^a   Shiba, Hiroaki ^a   Misawa, Takeyuki ^a   Ohashi, Toya ^a   Eto, Yoshikatsu ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; COMPLEMENTARY DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; GENETIC TRANSDUCTION; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS TISSUE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTIBODY FORMATION; CARCINOMA, HEPATOCELLULAR; CD40 LIGAND; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNITY, CELLULAR; LIVER NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED BUF; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54949113950     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00953.x     Document Type: Article

References (33)

1. Lopez LJ, Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2004; 20: 248-53.
2. Allen J, Venook A. Hepatocellular carcinoma: Epidemic and treatment. Curr Oncol Rep 2004; 6: 177-83.
3. Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg 2006; 10: 761-80.
4. Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12: 7239-49.
5. Kaido T. Characteristics and quality of randomized controlled trials in the treatment of hepatocellular carcinoma. Dig Dis Sci 2007; [Epub ahead of print].
6. Kassahun WT, Fangmann J, Harms J, Hauss J, Bartels M. Liver resection and transplantation in the management of hepatocellular carcinoma: A review. Exp Clin Transplant 2006; 4: 549-58.
7. Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 2004; 39: 919-26. Review.
8. Nuzzo G, Giuliante F, Gauzolino R, Vellone M, Ardito F, Giovannini I. Liver resections for hepatocellular carcinoma in chronic liver disease: experience in an Italian centre. Eur J Surg Oncol 2007; [Epub ahead of print].
9. Magott-Procelewska M. Costimulatory pathways as a basic mechanism of activating a tolerance signal in T cells. Ann Transplant 2004; 9: 13-18.
10. + T cells. J Immunol 1993; 151: 2497-510.
11. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
12. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-3.
13. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann Rev Immunol 1998; 16: 111-35.
14. Schmitz V, Barajas M, Wang L et al. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology 2001; 34: 72-81.
15. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005; 11: 8816-21.
16. Liu Y, Xia D, Li F, Zheng C, Xiang J. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005; 12: 122-32.
17. Koppold B, Sauer G, Buening H et al. Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. J Cancer Res Clin Oncol 2006; 132: 787-94.
18. Loskog A, Totterman TH. CD40L: A multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 2007; 7: 23-8.
19. Kimura T, Ohashi T, Kikuchi T, Kiyota H, Eto Y, Ohishi Y. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector. Cancer Gene Ther 2003; 10: 833-9.
20. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict. from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-7.
21. Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004; 64: 6775-82.
22. Hernandez MG, Shen L, Rock KL. CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help. J Immunol 2007; 178: 2844-52.
23. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 1999; 10: 1375-87.
24. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte/ macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999; 190: 125-33.
25. Couderc B, Zitvogel L, Douin-Echinard V et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 1998; 5: 163-75.
26. Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 1997; 8: 1935-43.
27. Kanegae Y, Lee G, Sato Y, Tanaka M, Sakaki T, Sugano S. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific cre recombinase. Nucleic Acids Res 1995; 23: 3816.
28. Niwa H, Yamamura K, Miyazaki Y. Efficient selection for high expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193.
29. Kanegae Y, Makimura M, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994; 47: 157-66.
30. Kikuchi T, Akasaki Y, Homma S et al. Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother 2000; 23: 184-9.
31. + and B lymphocytes in transplantation immunity. Transplantation 1993; 55: 1356-61.
32. Fujieda M, Oishi N, Kurashige T. Antibody to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment. Cli Exp Immunol 1997; 107: 120-6.
33. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000; 60: 6391-5.